O	0	8	Efficacy
O	9	12	and
O	13	19	safety
O	20	22	of
B-intervention	23	34	palbociclib
I-intervention	35	39	plus
I-intervention	40	49	endocrine
I-intervention	50	57	therapy
O	58	60	in
B-location	61	66	North
I-location	67	75	American
O	76	81	women
O	82	86	with
O	87	94	hormone
O	95	103	receptor
O	103	104	-
O	104	112	positive
O	112	113	/
O	113	118	human
O	119	128	epidermal
O	129	135	growth
O	136	142	factor
O	143	151	receptor
O	152	153	2
O	153	154	-
O	154	162	negative
O	163	173	metastatic
O	174	180	breast
O	181	187	cancer
O	187	188	.

O	189	200	Palbociclib
O	201	203	is
O	204	205	a
O	206	212	cyclin
O	212	213	-
O	213	222	dependent
O	223	229	kinase
O	230	231	4
O	231	232	/
O	232	233	6
O	234	243	inhibitor
O	244	253	indicated
O	254	257	for
O	258	267	treatment
O	268	270	of
O	271	278	hormone
O	279	287	receptor
O	287	288	-
O	288	296	positive
O	296	297	/
O	297	302	human
O	303	312	epidermal
O	313	319	growth
O	320	326	factor
O	327	335	receptor
O	336	337	2
O	337	338	-
O	338	346	negative
O	347	355	advanced
O	356	362	breast
O	363	369	cancer
O	370	372	in
O	373	384	combination
O	385	389	with
O	390	399	endocrine
O	400	407	therapy
O	407	408	.

O	409	411	We
O	412	424	investigated
O	425	428	the
O	429	437	efficacy
O	438	441	and
O	442	448	safety
O	449	451	of
O	452	463	palbociclib
O	464	466	in
O	467	475	patients
O	476	484	enrolled
O	485	487	in
O	488	493	North
O	494	501	America
O	502	508	during
O	509	512	two
O	512	513	-
O	513	518	phase
O	519	520	3
O	521	527	trials
O	527	528	:
O	529	535	PALOMA
O	535	536	-
O	536	537	2
O	538	539	(
O	539	540	n
O	541	542	=
B-total-participants	543	546	267
O	546	547	,
O	548	552	data
O	553	559	cutoff
O	559	560	:
O	561	564	May
O	565	567	31
O	567	568	,
O	569	573	2017
O	573	574	)
O	575	578	and
O	579	585	PALOMA
O	585	586	-
O	586	587	3
O	588	589	(
O	589	590	n
O	591	592	=
B-total-participants	593	596	240
O	596	597	,
O	598	602	data
O	603	610	cutoffs
O	610	611	:
O	612	617	April
O	618	620	13
O	620	621	,
O	622	626	2018
O	626	627	,
O	628	631	for
O	632	639	overall
O	640	648	survival
O	648	649	,
O	650	657	October
O	658	660	23
O	660	661	,
O	662	666	2015
O	666	667	,
O	668	671	for
O	672	675	all
O	676	681	other
O	682	690	outcomes
O	690	691	)
O	691	692	.

O	693	695	In
O	696	702	PALOMA
O	702	703	-
O	703	704	2
O	704	705	,
B-eligibility	706	715	treatment
I-eligibility	715	716	-
I-eligibility	716	718	na
I-eligibility	718	719	Ã¯
I-eligibility	719	721	ve
I-eligibility	722	736	postmenopausal
I-eligibility	737	745	patients
I-eligibility	746	750	with
I-eligibility	751	759	advanced
I-eligibility	760	766	breast
I-eligibility	767	773	cancer
O	774	778	were
O	779	789	randomized
O	790	791	2
O	791	792	:
O	792	793	1
O	794	796	to
O	797	808	palbociclib
O	809	810	(
O	810	813	125
O	814	816	mg
O	816	817	/
O	817	818	d
O	818	819	;
O	820	821	3
O	822	827	weeks
O	828	830	on
O	830	831	/
O	831	832	1
O	833	837	week
O	838	841	off
O	842	843	[
O	843	844	3
O	844	845	/
O	845	846	1
O	846	847	]
O	847	848	)
O	849	853	plus
O	854	863	letrozole
O	864	865	(
O	865	866	2
O	866	867	.
O	867	868	5
O	869	871	mg
O	871	872	/
O	872	873	d
O	873	874	,
O	875	885	continuous
O	885	886	)
O	887	889	or
B-control	890	897	placebo
I-control	898	902	plus
I-control	903	912	letrozole
O	912	913	.

O	914	916	In
O	917	923	PALOMA
O	923	924	-
O	924	925	3
O	925	926	,
B-eligibility	927	935	patients
I-eligibility	936	939	who
I-eligibility	940	950	progressed
I-eligibility	951	953	on
I-eligibility	954	959	prior
I-eligibility	960	969	endocrine
I-eligibility	970	977	therapy
O	978	982	were
O	983	993	randomized
O	994	995	2
O	995	996	:
O	996	997	1
O	998	1000	to
O	1001	1012	palbociclib
O	1013	1014	(
O	1014	1017	125
O	1018	1020	mg
O	1020	1021	/
O	1021	1022	d
O	1022	1023	;
O	1024	1025	3
O	1025	1026	/
O	1026	1027	1
O	1027	1028	)
O	1029	1033	plus
O	1034	1045	fulvestrant
O	1046	1047	(
O	1047	1050	500
O	1051	1053	mg
O	1053	1054	,
O	1055	1058	per
O	1059	1067	standard
O	1068	1070	of
O	1071	1075	care
O	1075	1076	)
O	1077	1079	or
O	1080	1087	placebo
O	1088	1092	plus
O	1093	1104	fulvestrant
O	1104	1105	;
O	1106	1109	pre
O	1109	1110	/
O	1110	1124	perimenopausal
O	1125	1133	patients
O	1134	1142	received
O	1143	1150	ovarian
O	1151	1162	suppression
O	1163	1167	with
O	1168	1177	goserelin
O	1177	1178	.

O	1179	1190	Palbociclib
O	1191	1195	plus
O	1196	1205	endocrine
O	1206	1213	therapy
O	1214	1223	prolonged
B-outcome	1224	1230	median
I-outcome	1231	1242	progression
I-outcome	1242	1243	-
I-outcome	1243	1247	free
I-outcome	1248	1256	survival
O	1257	1259	vs
O	1260	1267	placebo
O	1268	1272	plus
O	1273	1282	endocrine
O	1283	1290	therapy
O	1291	1293	in
O	1294	1299	North
O	1300	1308	American
O	1309	1317	patients
O	1318	1319	(
O	1319	1325	PALOMA
O	1325	1326	-
O	1326	1327	2
O	1327	1328	:
B-iv-cont-median	1329	1331	25
I-iv-cont-median	1331	1332	.
I-iv-cont-median	1332	1333	4
O	1334	1336	vs
B-cv-cont-median	1337	1339	13
I-cv-cont-median	1339	1340	.
I-cv-cont-median	1340	1341	7
I-cv-cont-median	1342	1348	months
O	1348	1349	,
O	1350	1356	hazard
O	1357	1362	ratio
O	1362	1363	,
O	1364	1365	0
O	1365	1366	.
O	1366	1368	54
O	1369	1370	[
O	1370	1372	95
O	1372	1373	%
O	1374	1376	CI
O	1376	1377	,
O	1378	1379	0
O	1379	1380	.
O	1380	1382	40
O	1382	1383	-
O	1383	1384	0
O	1384	1385	.
O	1385	1387	74
O	1387	1388	]
O	1388	1389	,
O	1390	1391	P
O	1392	1393	<
O	1394	1395	.
O	1395	1399	0001
O	1399	1400	;
O	1401	1407	PALOMA
O	1407	1408	-
O	1408	1409	3
O	1409	1410	:
B-iv-cont-median	1411	1412	9
I-iv-cont-median	1412	1413	.
I-iv-cont-median	1413	1414	9
O	1415	1417	vs
B-cv-cont-median	1418	1419	3
I-cv-cont-median	1419	1420	.
I-cv-cont-median	1420	1421	5
I-cv-cont-median	1422	1428	months
O	1428	1429	,
O	1430	1436	hazard
O	1437	1442	ratio
O	1442	1443	,
O	1444	1445	0
O	1445	1446	.
O	1446	1448	52
O	1449	1450	[
O	1450	1452	95
O	1452	1453	%
O	1454	1456	CI
O	1456	1457	,
O	1458	1459	0
O	1459	1460	.
O	1460	1462	38
O	1462	1463	-
O	1463	1464	0
O	1464	1465	.
O	1465	1467	72
O	1467	1468	]
O	1468	1469	,
O	1470	1471	P
O	1472	1473	<
O	1474	1475	.
O	1475	1479	0001
O	1479	1480	)
O	1480	1481	.

B-outcome	1482	1491	Objective
I-outcome	1492	1500	response
O	1501	1504	and
B-outcome	1505	1513	clinical
I-outcome	1514	1521	benefit
I-outcome	1522	1530	response
I-outcome	1531	1536	rates
O	1537	1541	were
O	1542	1549	greater
O	1550	1554	with
O	1555	1566	palbociclib
O	1567	1569	vs
O	1570	1577	placebo
O	1578	1580	in
O	1581	1586	North
O	1587	1595	American
O	1596	1604	patients
O	1605	1607	in
O	1608	1612	both
O	1613	1619	trials
O	1619	1620	.

O	1621	1626	While
O	1627	1634	overall
O	1635	1643	survival
O	1644	1648	data
O	1649	1652	are
O	1653	1656	not
O	1657	1660	yet
O	1661	1667	mature
O	1668	1671	for
O	1672	1678	PALOMA
O	1678	1679	-
O	1679	1680	2
O	1680	1681	,
B-outcome	1682	1688	median
I-outcome	1689	1696	overall
I-outcome	1697	1705	survival
O	1706	1709	was
O	1710	1719	increased
O	1720	1722	in
O	1723	1729	PALOMA
O	1729	1730	-
O	1730	1731	3
O	1732	1733	(
B-iv-cont-median	1733	1735	32
I-iv-cont-median	1735	1736	.
I-iv-cont-median	1736	1737	0
O	1738	1740	vs
B-cv-cont-median	1741	1743	24
I-cv-cont-median	1743	1744	.
I-cv-cont-median	1744	1745	7
I-cv-cont-median	1746	1752	months
O	1752	1753	,
O	1754	1760	hazard
O	1761	1766	ratio
O	1766	1767	,
O	1768	1769	0
O	1769	1770	.
O	1770	1772	75
O	1773	1774	[
O	1774	1776	95
O	1776	1777	%
O	1778	1780	CI
O	1780	1781	,
O	1782	1783	0
O	1783	1784	.
O	1784	1786	53
O	1786	1787	-
O	1787	1788	1
O	1788	1789	.
O	1789	1791	04
O	1791	1792	]
O	1792	1793	)
O	1793	1794	,
O	1795	1801	though
O	1802	1806	this
O	1807	1810	did
O	1811	1814	not
O	1815	1820	reach
O	1821	1832	statistical
O	1833	1845	significance
O	1846	1847	(
O	1847	1848	P
O	1849	1850	=
O	1851	1852	.
O	1852	1856	0869
O	1856	1857	)
O	1857	1858	.

O	1859	1865	Safety
O	1866	1874	profiles
O	1875	1877	in
O	1878	1883	North
O	1884	1892	American
O	1893	1901	patients
O	1902	1906	were
O	1907	1914	similar
O	1915	1917	to
O	1918	1923	those
O	1924	1926	of
O	1927	1930	the
O	1931	1938	overall
O	1939	1950	populations
O	1950	1951	;
O	1952	1963	neutropenia
O	1964	1967	was
O	1968	1971	the
O	1972	1976	most
O	1977	1983	common
O	1984	1993	treatment
O	1993	1994	-
O	1994	2002	emergent
O	2003	2010	adverse
O	2011	2016	event
O	2016	2017	.

O	2018	2020	No
O	2021	2024	new
O	2025	2031	safety
O	2032	2039	signals
O	2040	2044	were
O	2045	2053	observed
O	2053	2054	.

O	2055	2057	In
O	2058	2065	summary
O	2065	2066	,
O	2067	2078	palbociclib
O	2079	2083	plus
O	2084	2093	endocrine
O	2094	2101	therapy
O	2102	2104	is
O	2105	2107	an
O	2108	2117	effective
O	2118	2127	treatment
O	2128	2134	option
O	2135	2138	for
O	2139	2144	North
O	2145	2153	American
O	2154	2159	women
O	2160	2164	with
O	2165	2172	hormone
O	2173	2181	receptor
O	2181	2182	-
O	2182	2190	positive
O	2190	2191	/
O	2191	2196	human
O	2197	2206	epidermal
O	2207	2213	growth
O	2214	2220	factor
O	2221	2229	receptor
O	2230	2231	2
O	2231	2232	-
O	2232	2240	negative
O	2241	2249	advanced
O	2250	2256	breast
O	2257	2263	cancer
O	2263	2264	.
